ReviewClinical advances in hematology & oncology : H&O2013
Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia.
Review in Clinical advances in hematology & oncology : H&O, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Trial
- Enasidenib in mutantBlood · 2017Trial
- Early warning and prevention of pneumonia in acute leukemia by patient education, spirometry, and positive expiratory pressure: A randomized controlled trial.American journal of hematology · 2016Trial
- Trial
- Understanding the Extent of Polypharmacy and its Association With Health Service Utilization Among Persons With Cancer and Multimorbidity: A Population-Based Retrospective Cohort Study in Ontario, Canada.Journal of pharmacy practice · 2024Article
- Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia.Frontiers in oncology · 2023Article
- Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents.European journal of haematology · 2022Article
- Co-management strategies for acute myeloid leukemia patients in the community setting.Frontiers in oncology · 2022Article
- Treatment of Acute Leukemia During COVID-19: Focused Review of Evidence.Clinical lymphoma, myeloma & leukemia · 2021Review
- Safety and Feasibility of Outpatient High Dose Cytarabine for Acute Myeloid Leukemia in the Brazilian Amazon.International journal of hematology-oncology and stem cell research · 2020Article
- Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome.Blood advances · 2020Article
- Article
- Article
- Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?Current hematologic malignancy reports · 2019Review
- Article
- Living with outpatient management as spouse to intensively treated acute leukemia patients.PloS one · 2019Article
- A Comparison of Inpatient and Outpatient-Based Chemotherapy Regimens for the Treatment of Acute Myeloid Leukaemia In The Elderly.The Ulster medical journal · 2019Article
- Developing an instrument to assess patient preferences for benefits and risks of treating acute myeloid leukemia to promote patient-focused drug development.Current medical research and opinion · 2018Article
- Outpatient care of patients with acute myeloid leukemia: Benefits, barriers, and future considerations.Leukemia research · 2016Review
- Outpatient management of intensively treated acute leukemia patients--the patients' perspective.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Adults with newly diagnosed or relapsed acute myeloid leukemia (AML) commonly receive intensive chemotherapy to achieve disease remission. In the United States and many other countries, it is standard practice that these patients remain hospitalized "preemptively" until blood count recovery, owing to the risk for overwhelming infections and bleeding during pancytopenia. This care policy requires hospitalization for an average of 3 to 4 weeks after completion of chemotherapy. However, highly effective oral prophylactic antimicrobials are now available, and transfusion support of outpatients has become routine in recent years. As a result, the care of patients with hematologic malignancies treated with intensive modalities is increasingly shifting from inpatient to outpatient settings. Benefits of this shift could include the reduced need for medical resources (eg, transfusions or intravenous antimicrobial therapy), improved quality of life (QOL), decreased rates of nosocomial infections, and lower costs. Increasing evidence indicates that select AML patients undergoing intensive remission induction or salvage chemotherapy can be discharged early after completion of chemotherapy and followed closely in a well-equipped outpatient facility in a safe and costeffective manner. Further demonstration that the current approach of preemptive hospitalization is medically unjustified, economically more burdensome, and adversely affects health-related QOL would very likely change the management of these patients throughout this country and elsewhere, resulting in the establishment of a new standard practice that improves cancer care.
Indexed as
Identifiers
24518520PMC4212516W4394704What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.